The oral route of administration has significant limitations in acute ACS settings, particularly in STEMI cases complicated by cardiogenic shock (CS) and cardiac arrest (CA), where rapid P2Y12 inhibition is crucial. This evidence concerns the gene P2RY12 and cardiac arrest.